Navigation Links
Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Date:7/1/2009

CHADDS FORD, Pa., July 1 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its second quarter financial results on July 30, 2009 and will host a conference call and webcast at 9:00 a.m. ET that day to discuss these results.

David P. Holveck, president and chief executive officer, Nancy J. Wysenski, chief operating officer, Alan Levin, chief financial officer, Ivan Gergel, M.D., executive vice president of research and development and Blaine Davis, vice president, corporate affairs will host the call.

Investors and other interested parties may call 800-901-5248 (domestic) or 617-786-4512 (international) and enter passcode 39225165. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from July 30 at 1:30 p.m. ET until 12:00 a.m. ET on August 7 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 74683162.

A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on August 7. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R) for the palliative treatment of advanced prostate cancer, and SUPPRELIN(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
3. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
4. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
5. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
6. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
7. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
8. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
9. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
10. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
11. Atlantic Pharmaceuticals, Inc. Announces Completion of Successful Pre-IND Meeting with FDA for Abuse Deterrent Narcotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... ... 2016 , ... The Florida Hospital Tampa Wound Healing Institute ... (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute as ... facilities have earned this distinction. This is the second time the Florida Hospital ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... County, a Property owned by an affiliate of Seavest, has won a prestigious ... Medicine Southern Chester County ambulatory care center (ACC) was named “Best New Development, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Australia Ophthalmic ... new report, "Australia Ophthalmic Lasers Market Outlook to 2022", ... market. The report provides value, in millions of US ... market segements - Excimer Lasers, Femtosecond Lasers and YAG ... distribution shares data for each of these market segements, ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
Breaking Medicine Technology: